TY - JOUR
T1 - Acute leukemia during pregnancy
T2 - A single institutional experience with 17 cases
AU - Greenlund, L. J.S.
AU - Letendre, L.
AU - Tefferi, A.
PY - 2001
Y1 - 2001
N2 - We reviewed the medical records of 17 consecutive patients with concomitant acute leukemia and pregnancy seen at our institution over a 37-year period. Fifteen cases each were either newly diagnosed or classified as acute myeloid leukemia (AML). Seven diagnoses (41%) occurred in the first, 7 (41%) in the second, and 3 (18%) in the third trimester. In general, nine patients received chemotherapy while pregnant-eight in the second trimester and one in the third. The overall complete remission rate among the 13 patients with newly diagnosed AML was 69%, compared with 86% in those who were pregnant during chemotherapy. Long-term survival was documented in five of the nine complete responders. Three of four patients who elected to delay treatment until after delivery died within days of starting chemotherapy. Unintentional fetal loss occurred in four patients (29%), including two without exposure to chemotherapy. There were no instances of congenital malformation. The results from the current study confirm that pregnancy per se may not affect the outcome of chemotherapy in AML. In addition, it is suggested that treatment delays may compromise maternal outcome without improving pregnancy outcome.
AB - We reviewed the medical records of 17 consecutive patients with concomitant acute leukemia and pregnancy seen at our institution over a 37-year period. Fifteen cases each were either newly diagnosed or classified as acute myeloid leukemia (AML). Seven diagnoses (41%) occurred in the first, 7 (41%) in the second, and 3 (18%) in the third trimester. In general, nine patients received chemotherapy while pregnant-eight in the second trimester and one in the third. The overall complete remission rate among the 13 patients with newly diagnosed AML was 69%, compared with 86% in those who were pregnant during chemotherapy. Long-term survival was documented in five of the nine complete responders. Three of four patients who elected to delay treatment until after delivery died within days of starting chemotherapy. Unintentional fetal loss occurred in four patients (29%), including two without exposure to chemotherapy. There were no instances of congenital malformation. The results from the current study confirm that pregnancy per se may not affect the outcome of chemotherapy in AML. In addition, it is suggested that treatment delays may compromise maternal outcome without improving pregnancy outcome.
KW - Acute myeloid leukemia
KW - Chemotherapy
KW - Pregnancy
UR - http://www.scopus.com/inward/record.url?scp=0034895314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034895314&partnerID=8YFLogxK
U2 - 10.3109/10428190109060347
DO - 10.3109/10428190109060347
M3 - Article
C2 - 11378574
AN - SCOPUS:0034895314
SN - 1042-8194
VL - 41
SP - 571
EP - 577
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5-6
ER -